Top Markets
#1 Black Phoenix Black Phoenix +732.64%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.80%
#3 TENDIES TENDIES +22.99%
#4 THORChain THORChain +18.96%
#5 Biconomy Biconomy +18.30%
#6 MetaDAO MetaDAO +16.83%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +16.29%
#8 Pons Pons +16.01%
#9 Moolah Moolah +15.93%
#10 THORChain Yield THORChain Yield +13.92%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Rang in aandelen #5110
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Aandeelprijs
$58.70
Laatst gesynchroniseerd: 2024-01-23
Marktkapitalisatie
$2.98B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Mirati Therapeutics, Inc. (MRTX)

Categorie

Healthcare
Winst voor Mirati Therapeutics, Inc. (MRTX)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Mirati Therapeutics, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Mirati Therapeutics, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH